ҽҩ֪ʶ
ҽҩ֪ʶ
ҽҩ֪ʶ
ҽҩ֪ʶ
  • ڷJAK1ƼJyselecaʪԹؽձУ

    գձƳJyselecafilgotinib200mg100mgƬƶԳƷӦʪԹؽףRA˻ߣԤṹԹؽˡҩһµġÿտڷһεġѡJAK1Ƽڽ9»ձͶʡMHLW׼ܷ棬Jyselecaձͬһ죬ҲŷίԱ׼ƶһֻּοʪҩDMARDӦܵжضRA˻ߡ11³JyselecaԽ᳦ףUCӦ֢ҲŷҩƷ棬FDAڽ8·

  • ԱͿһALKԷΰ3о

    ΰȫ簩֢ͷԭNSCLCԼռΰ80-85%ALKԼռNSCLC3-5%ڰƷƷ֮ǰNSCLCߵ5ֻ5%ջ𹫲2ALKΰҩLorbrenaᣩXalkoriᣩһڼܰøALKԷСϸΰNSCLCͷͷIIICROWNоԽʾXalkoriȣLorbrenaƽչ72%HR=0.28p0.001­ڻʷߣ͹ۻORR82% vs 23%ȫCR71% vs 8

  • FDArilzabrutinibѪС֢ͨʸ!​

    ѪС֢ITPһֺġصԼ߽鵼ѪСƻѪС𣬵ѪҺѪСͣѪС֢׳ѪԻӰ졣ڽƤ̴Ʋ鸴еֿITPߣʵֿٺͳ־ûⷽ棬Դδҽ󡣡FDArilzabrutinibѪС֢ITPĿͨʸFTDrilzabrutinibһеĿڷ³ҰἤøBTKƼоʾrilzabrutinibܹ֢ϸ

  • NMPAɾоȲ㲿֫պڿ򾯸

    2020826գʳƷҩƷල֣FDAҩƷȫͨѶ2017516շġFDAҩƷȫͨѶFDAȷҩ│оInvokanaInvokametInvokamet XRȲ㲿֫ߡи£ɾغڿ򾯸档ڶ3ٴݵۣFDAҩ│оInvokanaInvokametInvokamet XRĴϢɾ˽֫շĺڿ򾯸档о׼ڽϽʳͶʱڽ2򲡳˻ߵѪǡڵʱԿо֫DZڻFDA2

  • ͿҩڷTYK2Ƽdeucravacitinibмؽ2ٴɹ

    20201110Ѷ /BIOON/ --ʱʩ󱦣BMSչͿҩdeucravacitinibBMS-986165мؽףPsAһڽеIIٴоĽоڻPsA˻пչ2ּdeucravacitinib6mg12mgÿһΣ밲ο˶ԱȡʾоﵽҪյȫؼҪյ㡣deucravacitinibǴٴоƶ߽鵼ԼĵһҲΨһһ͡ڷѡҰἤø2TYK2ƼܣdeucravacitinibмĹؼ3оPOETYK PSO-1

  • ܰϸѪЧΣ

    գŷίԱᣨEC׼CalquenceacalabrutinibᣩܰϸѪCLL˻ߣΪ1ΪһֵҩƷobinutuzumabǰûнܹƵCLL˻ߣ2ΪһֵҩƷǰܹһƷCLL˻ߡCLLdzİѪ͡Calquence201911»FDA׼CLLСϸܰSLL˻ߡ˴ŷ׼2IIIоELEVATE-TNASCENDĽ2оֱ֤ʵһCLLԼƸԻ

  • ΰƷŷ֣ķ+޻Ʒŷ׼

    գŷίԱᣨEC׼PD-1ƷOpdivoŷYervoyķ2ڵĺƣһEGFRͻALKλתԷСϸΰNSCLC˻ߡ˴׼3CheckMate-9LAݣʾǰûнܹƵתNSCLCУ뵥ûȣOpdivo+Yervoy+2ڻҩڣOSҪյ㣩޽չڣPFSҪյ㣩ܻʣORRҪյ㣩ӳ˻ʱ䣨DoROpdivo+Yervoy+2ڻƵİȫԷӳһNSCLC

  • ķվ

    ӦƤףADһص֢ƤҪΪҵԵʪƤòӤ׶ֻOlumiantĻҩɷΪbaricitinibҩһÿտڷһεѡԡJAK1JAK2ƼĿǰٴڶ֢ԼԼƣʪԹؽףRAмӦƤסϵͳԺǴȡJAKø4ֱ֣ΪJAK1JAK2JAK3TYK2JAK-ϸӲ֢Լķ̣ʾJAKƼɹ㷺

  • OlumiantʪԹؽôҩҩУ

    OlumiantĿǰٴڶ֢ԼԼƣʪԹؽףRAмӦƤסϵͳԺǴȡJAKø4ֱ֣ΪJAK1JAK2JAK3TYK2JAK-ϸӲ֢Լķ̣ʾJAKƼɹ㷺Ƹ֢ԼڼøУbaricitinibJAK1JAK2ֳǿҪJAK3߳100ĿǰOlumiantѻȫ60ңŷ˺ձ׼Ϊһֵҩϼװʣڶһֻּο

  • Ӧ֢ӦƤףЧΣˣ

    ӦƤףADһص֢ƤҪΪҵԵʪƤòӤ׶ֻԸʪƤ˯ȱʧʳԼӰӰ컼ߵգŷίԱᣨEC׼ڷJAKƼOlumiantbaricitinibһµӦ֢ʺϵͳƵжضӦƤףAD˻ߡ˴׼OlumiantAD3BREEZE-ADٴĿݣ1OlumiantضADߵ2ҩоBREEZE

  • мbimekizumab밢ľȣbimekizumab3ٴЧ

    գʱȣUCBͿҩbimekizumabжضȰ߿м˻3ٴоBE SUREϸһͷͷhead-to-headH2Hоbimekizumab밬ά콢ƷHumira֣ͨadalimumabľ˱ȽϡʾоﵽȫҪʹҪյ㣺HumiraȣbimekizumabƵĻƤʸߡBE SURENCT03412747һ˫äҩIIIоȽbimekizumabHumiraжضȰ߿м˻ߵЧͰȫԡоһ

  • ALK+/ROS1+СϸΰЧɫʹ˵

    LorlatinibALK+/ROS1+СϸΰORRΪ56.4%­ORRΪ74%36ALK+ΰ3ROS1ΰܹһ߻ƣLorlatinibʾ3ȫ⣬19ֻ߲⣬͹ۻORRΪ56.4%DCRΪ97.4%­ORRΪ74%­DCRΪ100%Ǹߵ̴Ѫ֢(82%3-425%)ˮ(71,8%)(38.5%)֤ʵLorlatinibALK+/ROS1+NSCLCнϸߵ­ڻԺõİȫԡᣨLorlatinibǵALK /

  • תȥƵֿǰٰmCPRCߵ

    911գThe Lancet Oncology߷һоʾ밢¬ȣתȥƵֿǰٰmCPRCߵCARDNCT02485691һġűǩٴо漰13ŷ޹ҹ62оġ18ꡢECOG PS2ֲȷΪmCPRCĻߣ22511󣬿黼Ϊ129¬黼Ϊ126ǰоʾ밢¬ȣƻߵ޽չڣPFSڣOSоҪ˻

  • תǰٰЧô

    Ӧ֢,ڽܹƷļתǰٰߵơŵ(Sanofi)˾з20106»FDA׼У20113»ŷEMA׼У20147»ձPMDA׼,ĿǰδҹСһһְϳɼ໯ǰɼҶȡãûɼҩơͨƻ˿ѺͼϸҪ΢òϸѺϸơҩ(prednisone)ƼԺϩɼ

  • 鵥ڹڻƸΰã

    ҩƷල֣NMPA׼PD-L1TecentriqatezolizumabϿѪƤӣVEGFAvastinδܹȫơгĸϸHCCߡIMbrave150оTecentriqAvastinʹÿŸƻߵԤ󡣸йΪйΰṩµѡ񣡡ΰйİ֢֮һÿϽ40Լ368,000൱ÿ쳬1000йΰߵƽ5ʽԼ15׼ǻIIIIMbrave150оĽ194й

  • ڷJAK1Ƽabrocitinib12жضӦƤ׻

    FDAabrocitinib100mg200mgҩ루NDA飬ҩһÿһΡڷJAK1Ƽ12жضӦƤףADߡabrocitinibһֿڷСӣѡԵJanusø1JAK1ӦƤףADһصġԤġͨʹ˥ƤԻ߼ճشӰ졣ڶٴУabrocitinibڻAD֢״кǿЧѸټabrocitinibļļǻһǿ3ٴĿĽ

  • NucalamepolizumabӦ֢Щ

    գŷҩƷ֣EMAҩNucalamepolizumabӪȨ루MAA3Ӧ֢ϸۺHESԱ-װϢ(CRSwNP)ϸѿԶѪףEGPAŷˣNucala׼ΪһָƷضϸSEAߡNucalaѱ׼3Ӧ֢SEAEPGAHESϸļSEAHESCRSwNPEGPAϸˮƽΪ֢Լ3MAAһϵйؼоĽЩ

  • ƷСϸΰô

    lorlatinibҩύǻһ/ٴڶ׶εݡڲͬнƵĻߵЧ54ALKROS1ԵNSCLCߣ߶ǾƻCNSתƵALK+/ROS1+NSCLCٴ275ALK+ROS1+NSCLCߣ߶תƲҶйALKҩǻƣ100mg qdƣORRԼԲORRڸݼƵͬΪEXP1δƣEXP2(֮ǰֻù)EXP33A֮ǰù+ƣ3B֮ǰù

  • ؽҩﰢ˹ʲôƣ˹ӡȰҩʲô

    ˹أApremilastOtezlaһ״ġڷѡø-4PDE-4Ƽ2014׺2015˹أApremilastOtezlaֱFDAŷ޼ܻ׼ڻмؽףPSAжضȰ߿мPlaque psoriasisơڶٴʾ˹أApremilastOtezla16ܣָסͷƤţ㣩мõƣ52ܾά֡ҩǹȥ20лмƵ׸ڷҩҲǹȥ15лмؽ׵׸ڷҩӡҩ

  • ȥͰ±ԭԵ֭ٻԸӲĸã

    PBCҪȥᣨ˼UDCAӦ𲻼ѺƲܵijֶƷսҩ±ᣨOCAΪPBCߴϣΪҩȥᡡûƣȥĿǰָƼPBCһҩҪûΪٽ֭ڣˮԵϸüյϸϸ͸ϸܶԵ֭ˣƵ֭ٻͼøALP-ȰתøGGT򵰰MIgMˮƽЧٴӦUDCAPBCף

共有177页首页上一页123456789下一页尾页
客服中心
联系方式
400-001-9763
- ѯ
ɨάѯ